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ABSTRACT
Aim The majority of hemodialysis patients are hyperphosphate-
mic. Hyperphosphatemia in these patients can lead to renal oste-
odystrophy, vascular calcification, cardiovascular events, and is 
independently associated with mortality risk. The aim of this study 
was to evaluate the effect of intravenous vitamin C on phosphorus 
level in hemodialysis patients.
Methods Using a double blind randomized clinical trial, a total 
of 60 qualified hemodialysis patients were randomly allocated in 
two intervention and control groups and serum phosphorus, CRP, 
calcium, albumin and PTH levels were measured. At the end of 
each hemodialysis session, intervention group received vitamin C 
vial (500mg/5cc) intravenously three times a week for 8 weeks 
and control group received normal saline in the same way. Data 
were collected before and after two months of treatment. Data 
were analyzed using independent t-test, paired t-test and chi-squ-
are test.
Results Vitamin C treated group had a significant decrease in 
phosphorus (p=0.01), CRP level (p=0.01) and Ca×P product 
(p=0.03). In contrast, there was no significant difference in phosp-
horous (p= 0.5) and CRP levels (p= 0.6) and Ca×P product (p=0.7) 
in the control group. In addition, there was no statistically signifi-
cant change in calcium (p=0.1), PTH (p=0.4) and albumin (p=0.4) 
levels in both groups.
Conclusion Intravenous vitamin C can significantly decrease 
phosphorus level in hemodialysis patients.
Key words: hemodialysis, phosphorus, vitamin C, hyperphospha-
temia, Ca×P product, CRP
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INTRODUCTION
Hyperphosphatemia is a common complication 
in patients with end stage renal disease (ESRD) 
undergoing hemodialysis. Untreated hyperp-
hosphatemia might lead to renal osteodystrophy, 
vascular calcification, and cardiovascular events 
causing increased morbidity and mortality (1). 
Studies suggest that serum phosphate greater than 
6.5 mg/dL is associated with 27% higher mor-
tality risk compared to patients with phosphate 
level of 2.4–6.5 mg/dL (2). Hence, phosphorus 
control in patients on hemodialysis constitutes 
one of the most important issues that nephrolo-
gists are faced with today. Successful control of 
phosphorus is one of the key aspects in the ma-
nagement of hemodialysis patients (3). However; 
phosphate control has not been significantly im-
proved over the past two decades (2).  Also asso-
ciation between change in calcium, phosphorous 
and their product (Ca×P product) and increa-
sed cardiovascular mortality and morbidity in 
ESRD patients undergoing chronic dialysis has 
been described (4). Maintenance hemodialysis 
patients are especially predisposed to vitamin C 
deficiency because of dietary restrictions, malnu-
trition and clearance of vitamin C during dialysis 
treatment and this deficiency may have an impor-
tant impact on patient outcomes (5). One single 
hemodialysis session may result in a 50 to75% 
decrease in plasma vitamin C level, which pre-
dicts adverse cardiovascular outcomes in main-
tenance hemodialysis patients (6). Therefore, to 
reach normal levels of vitamin C, it is necessary 
to prescribe vitamin C supplements to all hemo-
dialysis patients (5).
Considering the fact that vitamin C can reduce 
the CRP level and CRP reduction directly corre-
lates with phosphorus reduction (7, 8), we hypot-
hesized that vitamin C can decrease phosphorus 
level in hemodialysis patients. The purpose of 
this study was to evaluate the effect of intrave-
nous vitamin C on phosphorus level in hemodi-
alysis patients.
PATIENTS AND METHODS
This study was a randomized double blind place-
bo-controlled clinical trial to evaluate the effect of 
intravenous vitamin C on phosphorus level in he-
modialysis patients. A total of 60 hemodialysis pa-
tients in Imam Khomeini Hospital, Sari, Iran, were 
included in the study from 5/22/2010 to 8/19/2010. 
Patients with the age range of 20-70 years and se-
rum phosphorus level above 5.5 mg/dl that had 
been hemodialysed three times a week on 4 hour 
sessions for at least 6 months prior to the trial, were 
enrolled in the study. Exclusion criteria were hi-
story of malignancy, malnutrition, severe cardiac 
or respiratory or liver disease, history of vitamin C, 
vitamin D, alcohol, oil fish and immunosuppressi-
ve drugs consumption during 2 months prior to the 
trial. Patients who refused to continue the study at 
any time or got systemic disease during the study 
were also excluded from the study. A list of random 
number generated by the random-number table 
was employed to allocate eligible patients into in-
tervention and control groups. Intervention group 
received vitamin C vial (500mg/5cc) intravenously 
from the venous line at the end of each hemodial-
ysis session three times a week for a period of 8 
weeks and control group received 5cc normal sali-
ne as placebo in the same way. Neither patients nor 
clinicians were aware of the allocated group. 
At the beginning of the study and before the last 
hemodialysis session, 10cc fasting venous blood 
samples were taken from the patients in order to 
measure serum phosphorus (P), calcium (Ca), 
CRP and parathyroid hormone (PTH) levels. Pati-
ents were asked not to change their nutrition, drugs 
and physical activity during the study. Phosphorus 
level was measured using Pars Azmoon Com-
pany Kit and photometric technique by BT3000 
and serum total calcium was measured with ort-
ho-cresolphthalein complexone (o-CPC) and then 
the Ca×P product was calculated. Serum CRP was 
measured with Norway Kit (England) and Nephe-
lometric method and PTH level by radio immuno-
assay technique and Gamma Counter. Moreover, 
all patients in the two groups received calcium-
based phosphate binder (calcium carbonate) and 
those who received aluminum hydroxide were 
excluded from the study. In both groups patients 
were dialyzed by Fresenius 4008B Hemodialysis 
Machine and single use polysulfone membrane. 
Dialysate calcium concentration was 1.2 mmol /L 
and all patients had arteriovenous (AV) fistula. 
Data were collected and analyzed using SPSS 
version 16 and chi-square test, Fisher exact test, 
independent and paired t-test. 
Approval from the Mazandaran University of Me-
dical Sciences Ethics Committee and informed 
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written consent from patients were obtained. This 
study was registered in a clinical trials database 
(IRCT138904224365N1; http://www.irct.ir).  
RESULTS  
Sixty eligible hemodialysis patients were re-
cruited in the period 5/22/2010 - 8/19/2010 and 
randomized into two groups. Two patients wit-
hdrew from the study (one patient in placebo 
group died and one patient in vitamin C group 
refused to continue the study) (Figure 1). Com-
plete data were obtained from 58 hemodialysis 
patients with a mean age of 59.7 (14.6) years for 
the vitamin C group and 60.6 (13.3) years for the 
controls, which showed no significant difference 
between the two groups (p=0.7). The mean dura-
tion of hemodialysis in intervention and control 
group was 29±16.0 and 30.1±22.1 months, res-
pectively, with no statistical significant differen-
ces between the two groups (p=0.8). 
As shown in Table 1, there was no statistically 
significant difference in demographic and baseli-
ne characteristics of the patients between the two 
study groups.
There was no significant differences in phospho-
rus (p=0.8), CRP (p=0.8), calcium (p=0.6) and 
PTH (p= 0.3) levels among the groups at the ba-
seline. As shown in Table 2, compared to their 
baseline level, vitamin C treated group showed 
a significant decrease in phosphorus (p=0.013) 
and CRP levels (p=0.042), and Ca×P product 
(p=0.033) ( Figure 2, Figure 3). In contrast, the-
re were no significant differences in these para-
meters in the placebo group. Furthermore, mean 
differences (after – before) of phosphorus, CRP 
and Ca×P product were statistically significant 
Variables
No (%) of patients in 
group
p
Vitamin C
(n=29)
Placebo
(n=29)
Gender
Male 17 (58.6) 14 (48.3)
0.46
Female 12 (41.4) 15 (51.7)
Marital Status
Single 2 (6.9) 3 (10.3)
0.58
Married 27 (93.1) 26 (89.7)
Smoking
Yes 5 (17.2) 2 (6.9)
0.23
No 24 (82.8) 27 (93.1)
Cause of renal 
failure
Diabetes 6 (20.7) 11 (37.9)
0.34Hypertension 13 (44.8) 11 (37.9)
Other Causes 10 (34.5) 7 (24.1)
Table 1. Demographics and clinical characteristic in interven-
tion and control groups
Variable Group Before intervention Mean ± SD After intervention Mean ± SD p* After - before Mean ± SD p†
Phosphorus (mg/dl)
Placebo 6.02±2.37 6.2±2.02 0.5 0.18±1.53
0.013
Vitamin C 6.11±2.1 4.98±1.97 0.01 -1.12±2.28
Calcium (mg/dl)
Placebo 8.34±0.9 8.24±0.4 0.5 -0.9±0.84
0.226
Vitamin C 8.24±0.75 8.42±0.56 0.2 0.18±0.86
CRP (mg/dl)
Placebo 11.1±9.09 11.24±7.82 0.9 0.14±8.0
0.042
Vitamin C 10.96±8.15 7.27±6.72 0.01 -3.7±7.7
Albumin (mg/dl)
Placebo 4.42±0.5 4.34±0.4 0.5 -0.08±0.67
0.737
Vitamin C 4.45±0.4 4.42±0.3 0.7 -0.03±0.57
Ca×P product 
(Mg2×dl2)
Placebo 50.03±20.1 50.27±17.7 0.7 0.93±13.5
0.033
Vitamin C 50.97±15.9 41.83±16.6 0.03 -8.4±20.2
PTH (ng/l)
Placebo 198.5±120.3 194.6±115.4 0.3 -4.1±117.1
0.814
Vitamin C 201.6±115.6 197.8±119.6 0.2 -3.9±116.5
Table 2. Mean and standard deviation of phosphorus, Calcium, CRP, Albumin, PTH level and Ca x P product in hemodialysis 
patients before and after intervention in Vitamin C (n=29) and placebo (n=29) groups
p*, paired t-test; p†, independent t-test
Figure 1. Flow diagram of the progress through the phases of 
trial of two groups
Figure 2. Phosphorous differences (after - before) in both 
groups (mean and SEM)
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between the intervention and control groups. 
Changes in calcium, albumin and PTH levels 
were not different in both groups after the inter-
vention (Table2).
DISCUSSION 
The key and novel finding in the present study is a 
significant decrease in phosphorus level by eight 
week administration of intravenous vitamin C in 
hemodialysis patients. Considering the anti infla-
mmatory and antioxidant effect of vitamin C (7) 
the paralleled reduction in phosphorus and CRP 
levels in the present study could be explained by 
some mechanisms which include: decrease in 
the cellular destruction and shift of phosphorus 
from the intra cellular to extra cellular fluid, re-
covery of cellular injury due to antioxidant effect 
and increased renal phosphate excretion, effect 
on metabolic acidosis and extracellular shift of 
phosphorus and effect on NaPi cotransporter and 
reducing phosphorus expression in proximal tu-
bule (9). Adeney et al (10) suggested that higher 
serum phosphate concentration, although within 
the normal range, are associated with a greater 
prevalence of vascular and valvular calcification 
in people with moderate chronic kidney disease 
(CKD). Our study showed that vitamin C treated 
group, had a lower Ca×P product level after inter-
vention. Ganesh et al (11) declared that for every 
10 greater units of Ca×P product in hemodialysis 
patients, the relative risk of sudden death incre-
ased by 7%. Also, Mills et al (12) demonstrated 
that Ca×P product is associated with severity of 
aortic stenosis in hemodialysis patients. Chronic 
inflammation, as reflected by increased of inflam-
matory markers, such as CRP, is highly prevalent 
in hemodialysis patients (13) and increased level 
of CRP is a strong predictor of all-cause mortali-
ty, especially, the cardiovascular one in these pati-
ents (14). In this study, we found that the average 
concentration of CRP and phosphorus level was 
significantly lower in intervention group than in 
control group. Hung et al (15) observed a direct 
relationship between serum phosphorus and CRP 
in a cohort study. Moreover, Movilli et al (16) 
showed an association of the Ca×P product with 
the CRP levels. Block et al (7) have shown the 
CRP-lowering effect of vitamin C supplementa-
tion. Vitamin C represents anti-oxidant defense 
in blood and non-supplemented hemodialysis 
patients are at risk of vitamin C deficiency (6). 
Parenteral administration of ascorbic acid may be 
an approach to overcome problems of vitamin C 
deficiency in hemodialysis patients- in particular 
problems associated with iron overload, erythro-
poietin resistance and chronic inflammation (17). 
Fumeron et al (18) reported that oral administra-
tion of 250 mg/day of vitamin C after dialysis did 
not significantly change the oxidative stress and 
inflammation states, but the effect of high doses 
of intravenous administration was not clear. Pa-
renteral vitamin C can improve erythropoiesis 
and decrease CRP level in hemodialysis patients 
(17). Major concern regarding safety of vitamin 
C supplementation is its metabolism to oxalate, 
which may develop to secondary oxalises (19) 
and one of the possible limitations of the present 
study was the lack of plasma oxalate level mea-
surements. However, we used a dose of vitamin 
C that according to previous studies did not in-
crease the plasma oxalate level after 8 weeks of 
treatment (17, 20). The statistical power of the 
study was calculated. The results indicated that 
assuming phosphorous mean difference of 1.30 
(SD=1.75), a sample size of 29 in each group 
was adequate to provide 81% statistical power to 
compare study groups. 
In conclusion, this study demonstrated that intra-
venous administration of vitamin C was effective 
in decreasing the phosphorus level in hemodi-
alysis patients. The beneficial change made by 
intravenous vitamin C in phosphorus level intro-
duces vitamin C as an attractive agent for future 
research and its use for patients who are on main-
tenance hemodialysis.
Figure 3. Ca x P product (Mg2×dl2) and CRP differences 
(after - before) in both groups (mean and SEM)
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